• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / A Class of Commonly Prescribed Anti-Depressants May Reduce inflammation in Inflammatory Arthritis

A Class of Commonly Prescribed Anti-Depressants May Reduce inflammation in Inflammatory Arthritis

March 14, 2010 By Arthritis Center

Synapse Receptors
Synapse Receptors

Limited data have suggested that the selective-serotonin reuptake inhibitors (SSRIs) may have anti-inflammatory properties in addition to their antidepressant effects.  Here, Sacre et al (Arthritis Rheum 2010; 62(43): 683) explore the mechanisms of two SSRIs (fluoxetine and citalopram) in models of experimental arthritis.

Methods

Inflammation was induced in the paws of male DBA/1 mice by immunizing with type II collagen and adjuvant (i.e. the collagen induced arthritis model of inflammatory arthritis).  Thereafter, mice were treated with either fluoxetine, citalopram, or an inert vehicle.  Clinical characteristics of the mice, immunoglobulin levels, inflammatory cytokines, and articular histology were compared between groups.   Next, the ex vivo effect of increasing concentrations of fluoxetine and citalopram on cytokine profiles and signaling through Toll-like receptors (TLRs) in murine marrow-derived macrophages and in cultured human macrophages and synoviocytes.

Results

There was a dose dependent decrease in quantitative measures of disease activity, paw swelling, histologic evidence of inflammation and erosive damage, and serum IL-12 with increasing doses of fluoxetine.  Fluoxetine did not affect serum anti-collagen antibody levels.  Effects were similar, but to a lesser magnitude, in citalopram treated mice.

In murine marrow-derived macrophages, both fluoxetine and citalopram inhibited cytokine production induced by TLRs 3,7, and 9 (but not TLR4) in a dose-dependent manner.  In human cultured macrophages, both fluoxetine and citalopram inhibited activation of TLRs 3 and 8.  In human synovial membrane cultures, both fluoxetine and citalopram inhibited the spontaneous production of TNF and IL-6, an effect that was not due to the effects of increasing serotonin or reduced cellular viability.

Conclusions

Fluoxetine and citalopram reduced the signs of murine inflammatory arthritis, reduced TLR induced cytokine production in murine marrow-derived macrophages, and reduced cytokine production in human macrophages and synovium culture ex vivo.

Editorial Comment

These results are interesting, and support a potential mechanism whereby SSRIs may play a role in ameliorating inflammatory arthritis.  However, there are no human data regarding their short or long term ability to reduce inflammation, modify synovitis, or abrogate erosive articular damage.  Thus, there are many more research steps required to support the use of this class of drugs in humans with inflammatory arthritis.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy